ERY974

We used ERY22, a T-cell engager developed as a monkey surrogate of the human therapeutic candidate ERY974, an anti-GPC3/CD3 T-cell engager...Interindividual variability in cytokine production and cytotoxicity correlated with chromatin accessibility at loci associated with these processes. These findings advance understanding of personalized risk prediction and management of CRS in clinical settings.

P1, N=179, Active, not recruiting, Chugai Pharmaceutical | Recruiting --> Active, not recruiting

P1, N=179, Recruiting, Chugai Pharmaceutical | Trial completion date: Sep 2024 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Dec 2025

P1, N=158, Recruiting, Chugai Pharmaceutical

ERY974 exerts strong anti-tumor activity against a variety of tumor models including those with a non-inflamed phenotype. In this talk, I will discuss the detailed preclinical characterization of ERY974, including the cytokine release mechanism and potential combination therapies.

The observed responses and CRS side effects are markers of ERY974 biologic activity. At doses below 0.81 μg/kg (regimen A), ERY974 was generally well tolerated with a manageable toxicity profile, including ERY-induced CRS which was manageable with steroid administration and anti-IL6R therapy. Further research is required to determine if combined prophylactic anti-IL6R and steroid therapy is a more effective strategy for managing CRS.